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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
Methotrexate (MTX) is an effective treatment in partially or totally reducing the symptoms of
Myasthenia Gravis (MG) patients.
STUDY DESIGN: Review of three English language studies; one Case Series Study following
3 patients with concomitant MG and Rheumatoid Arthritis treated with MTX published in 2014,
one Single-Blind Randomized Control Trial (RCT) comparing MTX and AZA (Azathioprine)
published in 2011, and one Double-blind, placebo-controlled Randomized Control Trial
published in 2016.
DATA SOURCES: Three primary research studies published in peer reviewed journals; found
on the PubMed database. Each study’s results included patient oriented outcomes that were
relevant to this selective EBM review.
OUTCOMES MEASURED: Each study assessed the MG outcomes and quality of life
measures after treatment with Methotrexate. The two RCTs used the following assessment tools
to quantify their outcomes: Quantitative MG (QMG) Score, Manual Muscle Testing (MMT),
MG Quality of Life (MGQOL), MG-Activities of Daily Living (MG-ADL), Minimum
Manifestations Status (MMS), and MG Composite Change.
RESULTS: The Case Series Study showed an association between MTX and improved MG
symptoms; however it did not show cause and effect. The Single-Blind RCT compared MTX
and AZA (enrollment: AZA n = 15; MTX n = 16). Similarities between both groups were found
in regards to MMS after 24 months (AZA n = 7; MTX n = 9; p = 0.83; ABI = .03; NNT = 34),
and safety; giving promise to MTX’s efficacy. The Double-blind, placebo-controlled RCT
(enrollment: MTX n = 25; Placebo n = 25) found MTX did not improve QMG, MMT, MGQOL,
MG-ADL, or MG Composite Change over 12 months. Withdrawals: Placebo n = 7; MTX n = 1;
no serious MTX-related adverse events were encountered. Both RCT’s data was determined to
be not statistically significant due to small enrollment size. P-values were >0.05 and 95% CI
were too wide to be precise.
CONCLUSION: Based on the Case Series Study and two RCTs, MTX is not an effective
treatment in partially or totally reducing the symptoms of MG patients.
KEY WORDS: Myasthenia Gravis, Methotrexate

Flyte, Methotrexate and Myasthenia Gravis 1
INTRODUCTION
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition associated
with weakness and fatigability of voluntary skeletal muscles of the body3. Muscles most
commonly affected control eye movement, the eye lids, chewing, swallowing, coughing and
facial expressions; less commonly affected are the muscles used to control breathing and the
movement of extremities6. This review evaluates one Case Series Study and two Randomized
Control Trials (RCTs) which study Methotrexate (MTX) to determine if it can reduce or
eliminate the symptoms of MG patients.
It is estimated that 20 out of every 100,000 individuals in the United States have been
diagnosed with MG; this equates to approximately 60,000 people. MG is believed, however, to
be a significantly underdiagnosed disease and the prevalence is probably much higher. 6
In a 2009 study, costs related to the treatment of MG were higher than those of other
chronic neurological diseases. The average total annual health plan cost for MG patients was
$20,190. $15,675 of which was attributed to the treatment of MG. Match-paired controls had an
average total annual health plan cost of only $4,515. The MG annual costs were broken down as
follows: 23% in Home Health (includes IVIg costs), 17% in MD office visits, 8% in Pharmacy
costs (does not include IVIg costs), 27% in Inpatient services, and 23% in Outpatient services.
Total annual MG-related pharmacological costs were $9.4 million. Pharmacological costs were
as follows: 85% IVIg, 9.3% non-steroidal immunosuppressants, 5.7% cholinesterase inhibitors,
and 0.2% corticosteroids.7
MG’s muscle weakness is due to circulating antibodies which are produced by plasma
cells, part of the body’s own immune system, which block or destroy as much as 80% of
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acetylcholine receptors at the postsynaptic junctions. This leads to the inhibition of skeletal
muscle contractions.3,6 Common symptoms include ptosis, blurred vision, diplopia, dysphonia,
difficulty chewing, dysphagia, extremity weakness, muscle fatigue and dyspnea. Muscle
weakness tends to increase with continued use and improves with periods of rest. Symptoms
vary for each patient and can fluctuate throughout a patient’s life. MG occurs in all races, both
genders and at any age. No strong genetic components have not been found, however it does
occasionally occur in more than one member of a family. MG is not an infectious disease,
therefore it is not contagious. Currently the cause of MG is unknown, and there is no cure for
this disease.6
There are various methods to treat MG; treatments are individualized to each patient
based on the severity of their symptoms, their sex, age, and degree of impairment. First-line
therapy for symptomatic treatment is an anti-acetylcholinesterase agent, which allows the
neurotransmitter Acetylcholine to remain at the neuromuscular junction longer so that more
receptors can be activated.6,11
Other first-line MG treatments are aimed at suppressing the immune system and the
associated antibody response to induce remission, prevent disease progression and restore
function at the neuromuscular junction11. Corticosteriods alone or in combination with other
immunosuppressant drugs are disease modifying agents for MG. Corticosteriods, such as
Prednisone, can be quite effective in reducing MG symptoms. However, they have serious doselimiting side effects including generalized immunosuppression, hyperglycemia, hypertension,
myopathy, weight gain, cataracts, and osteoporosis. Azathioprine (AZA) and Cyclosporine are
the only immunosuppressants proven to be effective for treating MG in RCTs when compared to
placebos.9 They are often used as steroid-sparing therapies, either reducing the need for or lower
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the corticosteroid doses, sparing the patient the steroid’s adverse side effects. These
immunosuppressants however, come with their own sets of side effects. Cyclosporine is
associated with hypertension, renal insufficiency, and hirsutism. AZA is associated with
systemic hypersensitivity, hepatotoxicity, and myelosuppression. 5
Methotrexate has been used and proven to be effective in the treatment of other
autoimmune disorders, such as Rheumatoid Arthritis (RA), Crohn’s disease, and Multiple
Sclerosis. It has many advantages include PO dosing once a week, a generic formulation, a
moderate side effect profile, inexpensive cost compared to other immunosuppressants like AZA,
easy accessibility, and the potential to be used for longer periods of time compared to
corticosteroids.2,5,11
OBJECTIVE
The objective of this selective Evidence Based Medicine (EBM) review is to determine
whether or not Methotrexate (MTX) is an effective treatment in partially or totally reducing the
symptoms of Myasthenia Gravis (MG) patients.
METHODS
The criteria used to select the studies for this EBM review include: the population studied
was over the age of 18 years old, who were diagnosed with Myasthenia Gravis class II, III, or IV,
who were stable on prednisone, but were not on any steroid-sparing immunosuppressants. Table
1 provides additional demographics and characteristics for the three studies included in this
review which include one Case Series Study and two Randomized Control Trials. The common
intervention among the studies was MTX. Comparison groups in the two RCTs included
experimental groups that received AZA in one study or a placebo in the second study. Outcomes
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measured included MG outcomes and quality of life measures, all of which assess MG symptom
improvement.
The studies were found by the author using key words “Myasthenia Gravis” and
“Methotrexate” in the PubMed database. All three studies were published in English in peer
reviewed journals. The sources were selected based on relevance to the clinical question and
inclusion of patient oriented outcomes (POEMs). Inclusion criteria for the sources included that
the studies must be a type of primary research study published within the last 15 years.
Exclusion criteria for the sources included patients under the age of 18, patients who had recent
thymectomies, or patients who were treated with an immunosuppressive therapy within the last
60 days with exception of Prednisone. A summary of the statistics reported or used in regard to
the two RCTs include: p-values and 95% CI (Confidence Interval) which were provided in the
studies, as well as CER (Control Event Rate), EER (Experimental Event Rate), ABI (Absolute
Benefit Increase), RBI (Relative Benefit Increase) and NNT (Number Needed to Treat) which
were calculated.
Table 1 – Demographics & Characteristics of included studies
Study
Karahmet3
(2014)
Heckman2
(2011)

Type
Case
Series
Study
Single
Blind
RCT

#
Pts
3

Age
(yrs)
31,36,
& 60

31

AZA:
42.7
+/-16.8
MTX:
47.9
+/14.8

Inclusion Criteria
Patients with
concomitant MG &
RA
Diagnosed within
previous 6 months
with MGFA class II,
III, or IV. Severity of
functional disability
of ADLs where
immunosuppressive
therapy is indicated
due to Pyridostigmine
failure as a
monotherapy.

Exclusion Criteria
N/A
Those with MG
confined to the
EOM or
concomitant illness
such as uncontrolled
thyroid disease or
additional
polymyositis, or
subjects with HBV
or HIV infections.

W
/D
0
6

Interventions
MTX 15 mg
weekly
MTX (17.5 mg
weekly + Folate
25 mg weekly)
or
AZA (2.5 mg/kg
daily)
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Barohn1
(2015)
Pasnoor4
(2014)
Pasnoor5
(2012)
Pasnoor9
(2016)

Double
Blind
RCT

50

18+
years
old;
26.6 to
87.2
(full
range)

MGFA grade 2, 3, or
4; stable on 10
mg/day of Prednisone
or equivalent with
alternate day dosing x
30 days.

Thymoma,
thymectomy (within
last 3 months),
tumor, infection,
hepatic / renal
insufficiency, or
ILD. On
immunosuppressive
therapy w/in last 60
days. Prior use of
MTX within prior 2
years. Daily NSAID
use.

8

MTX
or
Placebo
Dosing: 10 mg
weekly x 2
weeks, then 15
mg x 2 weeks,
then 20 mg
weekly until the
end of the study
(+ Folic acid
daily).

OUTCOMES MEASURED
For the Case Series Study, outcomes addressed were improvement in muscle weakness
and fatigue, however no specifics were provided in how the outcomes were measured over the
one year period of follow-up.3
For the Single-blind, MTX vs. AXA RCT, the Quantitative MG (QMG) score and the
MG Activities of Daily Living (MG-ADL) score were calculated to determine those with
Minimum Manifestations Status (MMS) of MG. Visits were scheduled at baseline, 1, 2, 4, and 6
months after study entry, followed by visits every 3 months for 2 years. At each visit the
patient’s progress was assessed by blind assessors. Outcomes were analyzed in as per-protocol
analysis in which data measurements of those who withdrew were censored after the date on
which they were no longer on the study medication. Data of all subjects were included in the
denominator for proportionate outcomes such as MMS, number of failures and “responders”.
Only those who reached sustained MMS up until the end of the 24-month study were considered
relevant. Patients were questioned at each visit in regards to compliance; with non-compliance,
the recorded dose reflected the dose that was taken. 2
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For the Double-blind, placebo-controlled RCT, MG outcomes and quality of life
measures were analyzed using the QMG, MG-ADL, Manual Muscle Testing (MMT), MG
Quality of Life (MGGOL), and MG Composite (MGC) change over 12 months; each were
evaluated every four weeks for 12 months. Data was analyzed in an intent-to-treat fashion, using
multiple imputation method for any missing data.1,9 See Table 2 for detailed descriptions of
outcome measurements.
Table 2 – Outcome Measurements & Descriptions
Outcome
Measurements
QMG

MG-ADL
MMT

MGQOL
MGC change over
12 months

Description of Measurements
13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength,
along with respiratory function. Scale of 0-3 for each item, with 0 = normal, 3 =
severe. Total score can range from 0-39. Time frame: Change from Baseline to
completion of study.1
8 item scale to assess MG symptoms. 0 = normal to 24 = severe. Time frame:
Change from Baseline to completion of study.1
Measures the strength of muscle groups in face, neck, arms, and legs; grading
amount of weakness. Normal = 0, mild = 1, moderate = 2, severe = 3, unable to
perform = 4. Total score can range from 0-76. Time frame: Change from Baseline
to Month 12.1
15 item patient-reported scale indicating how MG affects QOL per the past 7 days.
0 = not all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much. Total score
can range from 0-76. Time frame: Change from Baseline to Month 12.1
Composite of the QMG, MG-ADL, and MMT; each item was weighted and then
assigned a score. 0 = no effects of MG; 50 = being in the hospital on a ventilator.
Time frame: Change from Baseline to Month 12.1

RESULTS
In the Case Series Study, three patients with concomitant MG and RA were treated with
15 mg of MTX weekly and were followed for one year. The MTX treatment was given to treat
the RA, however all three patients experience beneficial effects in their MG symptoms of muscle
weakness and fatigue. The study did not provide continuous or dichotomous data in regards to
its results, nor was it a controlled trial. This study shows an association between MTX and
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improved MG symptoms; however it does not show cause and effect. When considering the side
effects of other immunosuppressive therapies, the researchers believed MTX could be an
effective treatment for MG. They acknowledge that more detailed studies are needed to
determine the exclusive role of MTX in regard to MG.3
Between 2005 and 2010, thirty-one subjects entered the Single-blind, MTX vs. AZA,
RCT. Twenty-four subjects were randomized to either MTX (n=11) or AZA (n=13). The
remaining seven subjects were not randomized. The majority were due to economic restraints
which did not allow them the ability to afford the more expensive AZA if randomized to that
group, therefore they were included in the MTX group (n=5). The two remaining participants
demanded the Standard of Care treatment of AZA (n=2). Baseline values between the MTX and
AZA group, including: duration of MG symptoms, proportion of Prednisone, baseline
bodyweight, MGFA severity grade, and QMG scores were similar. Results showed that similar
proportions of subjects in each group reached sustained MMS by the end of the 24 month trial
(AZA n = 7; MTX n = 9; p = 0.83). The MTX-group’s median time to sustained MMS was 10.5
months, where the AZA-group’s median time to sustained MMS was 12-15 months. The MMS
treatment outcomes were used to calculate ABI and NNT for this study; refer to Table 3.
Table 3
MMS Treatment Outcomes at 6-monthly intervals 2

AZA,
n (%)
MTX,
n (%)

6 months

12 months

18 months

24 months

2/15 (13%)

4/15 (27%)

5/15 (33%)

7/15 (53%)

3/16 (19%)

5/16 (31%)

5/16 (31%)

9/16 (56%)

Treatment Effect of MTX vs. AZA
CER
.53

EER
.56

RBI
.06

ABI
.03

NNT
34

P-Value
0.83
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According to this study, for every 34 patients treated with MTX, one additional MG
patient will sustain MMS, compared to patients treated with AZA. The p-value for the treatment
effect of MTX vs. AZA is 0.83. Since the p-value is >0.05, this shows that the findings are not
statistically significant due to the small subject group size of 31 participants. In regards to the
safety of the study, intolerable diarrhea (AZA n = 1; MTX n = 1), hearing loss and acne (AZA n
= 1), and loss of appetite (MTX n = 1) accounted for the study withdrawals, showing that AZA
and MTX were equally well tolerated.2
In summary, MTX has an earlier onset of action, similar efficacy and tolerability to AZA,
demonstrating prolonged remission from MG symptoms; also MTX may be the drug of choice in
financially constrained patients.2
Between April 2009 and September 2014, 50 subjects entered a Double-blind, placebocontrolled RCT (MTX n = 25; Placebo n = 25) at 19 sites across the U.S. and Canada conducted
by The Methotrexate in MG Investigators of the Muscle Study Group. Baseline values including
age, gender, self-reported race/ethnicity, clinical MG parameters and Prednisone dosing were
similar between both groups. The data included in this trial was continuous. The author reported
Change in mean from Baseline to Month 12 and t-test values; Table 4 summarizes these values.9
Table 4 – Treatment Effect of MTX vs. Placebo1,9
QMG Score (12 month change); method: t-test, 2 sided; groups: All Groups
MTX (95% CI)
Placebo (95% CI)
P-Value
MTX – Placebo (95% CI)
-1.4 (-2.9 to 0.1)
0.3 (-1.8 to 2.4)
0.29
-1.7 (-4.9 to 1.5)
MMT (12 month change); method: t-test, 2 sided; groups: All Groups
MTX (95% CI)
Placebo (95% CI)
P-Value
MTX – Placebo (95% CI)
-5.5 (-7.4 to 3.8)
-3.3 (-6.6 to 0.1)
0.28
-2.2 (-6.3 to 1.8)
MGQOL (12 month change); method: Wilcoxon (Mann-Whitney); groups: All Groups
MTX (95% CI)
Placebo (95% CI)
P-Value
MTX – Placebo (95% CI)
-4.6 (-9.1 to 0.1)
-3.7 (-8.4 to 1.0)
0.82
-0.9 (-7.2 to 5.4)
MG-ADL (12 month change); method: t-test, 2 sided; groups: All Groups
MTX (95% CI)
Placebo (95% CI)
P-Value
MTX – Placebo (95% CI)
-1.2 (-2.3 to 0.5)
0.26 (-0.9 to 1.5)
0.21
-1.5 (-3.7 to 0.8)
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MG Composite Change over 12 months; method: t-test, 2 sided; groups: All Groups
MTX (95% CI)
Placebo (95% CI)
P-Value
MTX – Placebo (95% CI)
-4.6 (-6.4 to 2.7)
-1.3 (-3.7 to 1.1)
0.09
-3.3 (-7.1 to 0.5)
*General Note – if a study participant terminated their participation, their last results were pulled forward.

The estimate of the treatment effect is not precise due to the fact that all of the p-values
are >0.05, showing that they are not statistically significant due to the small sample size. The
small sample size also attributes to the CI ranges being too wide to be precise. One participant
from the MTX group withdrew from the study due to travel problems. Seven participants from
the Placebo group withdrew from the study due to the following reasons: 3 due to worsening of
symptoms, 1 due to myalgia, 1 due to comorbid illness, 1 due to elevated LFTs, and 1 due to
death (stroke). Safety was assessed by adverse event reporting. No MTX subjects experienced
any serious adverse events, therefore the study was deemed safe. 23 out of 25 (92%) participants
from each group experienced some form of adverse event during the 12 month study, though
66% of these events were determined to be unrelated to the study. Most notably, the MTX group
experience more GI issues, including upset stomach, diarrhea or constipation (MTX 60%;
Placebo 44%). The MTX group also experienced more sinus infections or URIs (MTX 52%;
Placebo 28%). Both group’s participants experienced similar adverse events of general fatigue
(MTX 40%; Placebo 32%), general pain (MTX 52%; Placebo 56%; most common adverse
event), and worsening of MG symptoms (MTX 40%; Placebo 32%). 1,4,5,9
If MTX was proven to be effective in treating MG symptoms and reducing the use of
Prednisone, patients would have been able to benefit from MTX’s oral weekly dosing, including
a generic formulation, a moderate side effect profile, inexpensive cost, easy availability, and
potential use for longer periods of time. Unfortunately, MTX did not perform as the study had
hoped in reducing MG symptoms and improving the MG patient’s quality of life. 1,4,5,9
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DISCUSSION
MTX was well tolerated in both RCTs, showing only its typical benign side effects such
as GI upset. None of its more serious side effects surfaced during the studies, which include
stomatitis, rash, abnormal blood counts and pulmonary toxicity. Folic acid concomitantly is
required to help avoid these side effects. MTX is also teratogenic therefore women of childbearing age need to weigh the risk versus benefit of the use of this agent and use several forms of
birth control while using this agent.11
The major limitation of both RCTs was the smaller than anticipated size of the study due
to recruiting issues which, resulted in the data being not statistically significant 2,9. Also due to
the limited funding of one study, several socioeconomically challenged participants were not
about to be blinded due to AZA’s more expensive cost; this could have led to biases against
MTX when reporting symptom improvement2. The researchers of the most recent RCT also are
considering that perhaps their study was not long enough with its 12 months duration, they
referenced the prior RCT which compared AZA vs. MTX, which indicated that AZA required up
to 15 months to reach its full therapeutic potential. Another weakness the researchers considered
was that their study contained an older mean age in their population (mid-60s), which means the
study population included more late-onset MG subjects. The significance in this being that
patients with later onset of MG, tend to have a milder course of symptoms than younger patients
with MG. Milder symptoms could make detecting MTX’s benefits more difficult than in studies
with younger MG subjects. In the RCT comparing AZA vs. MTX, the mean age was 20 years
younger (mid-40s) and the MTX effects seemed more significant. 9,10
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CONCLUSION
The results of the Case Series Study and earlier Single-blind RCT showed promise that
MTX could be an effective treatment in partially or totally reducing the symptoms of MG
patients. However, the most recent Double-blind RCT suggests that MTX is no more effective
in reducing symptoms in MG than a placebo, when both are paired with Prednisone.
Dr. Daniel Drachman, MD from the John Hopkins School of Medicine Neurology
Department, responded to the disappointing negative results of this last MTX RCT. He feels that
a meaningful RCT for a new Gold Standard therapy for MG is nearly impossible at this point.
His belief stems from the fact that MG has been found to be the most treatable autoimmune
disease and therefore virtually all diagnosed MG patients start treatment immediately. This
makes recruitment for future studies extremely difficult, which both RCTs had experienced.
Also the early and effective treatment of MG patients with Prednisone, makes gauging any new
immunosuppressant’s effectiveness controversial and unreliable.8
When looking ahead at future therapies for MG, various monoclonal antibodies such as
Alemtuzumab, Belimumab, Eculizumab, Etanercept, and immunomodulatory drug Leflunomide
may be the next generation of Gold Standard MG agents. These chemical and biological agents
target different components of the immune system and may have a role in improving the
treatment of MG.11 Though MTX may not be the next Gold Standard agent for MG, researchers
did learn some valuable lessons for future studies. The MG community needs to carefully
consider which agents they study next. This is due to the need for larger numbers of participants,
a very limited commodity in this population, that will need to be followed for long periods of
time, to ensure the study captures the full treatment effect of the agent. 9

REFERENCES
1. Barohn R. Efficacy of methotrexate in myasthenia gravis. ClinicalTrials.gov Website.
https://clinicaltrials.gov/ct2/show/NCT00814138. Updated November 18, 2015. Accessed
January 2, 2016.
2. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of
methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
BMC Neurol. 2011;11:97-2377-11-97. doi: 10.1186/1471-2377-11-97 [doi].
3. Karaahmet OZ, Bal A, Dulgeroglu D, Bahceci HK, Cakci A. Methotrexate treatment in
myasthenia gravis. J Clin Neuromuscul Dis. 2014;16(2):106-107. doi:
10.1097/CND.0000000000000057 [doi].
4. Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn R, Muscle Study Group. Phase II trial of
methotrexate in myasthenia gravis (S16.002). Neurology. 2014;82 no. 10 Supplement
S16.002(April 8, 2014).
5. Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ, Muscle Study Group. Phase II trial of
methotrexate in myasthenia gravis. Ann N Y Acad Sci. 2012;1275:23-28. doi: 10.1111/j.17496632.2012.06804.x [doi].
6. What is Myasthenia Gravis (MG)? MFGA. http://myasthenia.org/. Accessed November 17,
2016.
7. Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of
treating myasthenia gravis in an insured U.S. population. Muscle & Nerve. 2012;45(3):363-366.
doi:10.1002/mus.22327.
8. Drachman DB. Comment: Methotrexate for patients with generalized myasthenia gravis.
Neurology. 2016;87(1):63-63. doi:10.1212/wnl.0000000000002818.
9. Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for patients
with generalized myasthenia gravis. Neurology. 2016;87(1):57-64.
doi:10.1212/wnl.0000000000002795.
10. Silvestri NJ, Wolfe GI, Lacomis D. Whatʼs in the Literature? Journal of Clinical
Neuromuscular Disease. 2016;18(2):108-117. doi:10.1097/cnd.0000000000000159.
11. Gotterer L, Li Y. Maintenance immunosuppression in myasthenia gravis. Journal of the
Neurological Sciences. 2016;369:294-302. doi:10.1016/j.jns.2016.08.057.

